Observational analysis highlights the role of methylglyoxal in TDP-43 and SOD1 interaction in ALS, suggesting new therapeutic avenues.
Introduction: Proteinopathy is a key feature of amyotrophic lateral sclerosis (ALS) that causes the loss of motor neurons. Glycated SOD1 increases the levels of phospho-TDP-43, a form that aggregates in the cytosol of neurons experiencing neurodegeneration in most ALS cases. Objective: Here, we evaluated whether TDP-43 interacts with SOD1 and the impact of methylglyoxal (MGO) and G93A SOD1, found in patients, on this interaction. Methodology: TDP-43-SOD1 interaction was observed in H4 cells using the bimolecular fluorescence complementation (BiFC) system. Results: Exposure to MGO reduced SOD1 activity and the levels of phospho-TDP-43 only in cells expressing WT SOD1. Our results showed that both WT and G93A SOD1 interact with TDP-43 in the nucleus and cytosol, with a greater proportion of cells showing cytosolic interactions between TDP-43 and the SOD1 mutant. MGO did not affect the interaction between TDP-43 and WT SOD1; however, it did lead to an increase in cytosolic inclusions at 0.4 mM MGO, a stress that resulted in a 50% reduction in cell viability. These inclusions did not colocalize with stress granules. Treatment with Cyclosporin A, an inhibitor of calcineurin (a phosphatase that dephosphorylates TDP-43), reduced the number of cells containing TDP-43 and WT SOD1 inclusions, as well as the cells showing TDP-43 and G93A SOD1 interactions in the cytosol. Conclusion: Thus, we conclude that damaged SOD1, produced by MGO, or G93A mutation disrupts TDP-43 phosphorylation, altering its location within the cell and inducing its aggregation, which are important markers of ALS.
No takes yet. Share an insight, caveat, or question.
Ribeiro et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: